Phase 2a study of the phosphatidylinositol-3-kinase (PI3K) inhibitor copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma.
Authors
Dreyling, MMorschhauser, F
Bouabdallah, K
Cunningham, D
Bron, D
Linton, Kim M
Assouline, S
Verhoef, G
Thiebtemont, C
Vitolo, U
Garcia-Vargas, J
Gorbatchevsky, I
Neves, M
Grunet, J
Hietneyer, F
Childs, B
Zinzani, P
Affiliation
Univ Klin Grosshadern LMU, Med Klin 3, Munich, GermanyIssue Date
2017